Some people can survive for a long time after endocrine treatment for prostate cancer, but it varies from person to person. At present, it is believed that the development of prostate cancer is influenced by androgen in the body, through endocrine therapy can inhibit the growth of tumor cells, control the progression of the disease, and reduce the probability of recurrence and metastasis as much as possible, and some people can survive for a long time through standardized treatment, so as to enhance the therapeutic effect as much as possible. The indications for endocrine therapy include: (1) metastatic prostate cancer; limited early or locally progressive prostate cancer, unable to undergo radical surgery or radiotherapy; neoadjuvant endocrine therapy before radical surgery or radical radiotherapy; adjuvant endocrine therapy in combination with radiotherapy; local recurrence after curative treatment, but unable to undergo local treatment; distant metastasis after curative treatment; and continuous androgen inhibition during the period of de-escalation resistance. A domestic study stated that the 1-, 3- and 5-year disease-specific survival rates of prostate cancer patients receiving endocrine therapy were 93.2%, 68.3% and 40.1%, respectively. If prostate cancer is suspected or diagnosed, it is recommended to go to regular hospitals for comprehensive assessment of the condition and follow the doctor’s instructions to cooperate with the treatment, so as not to delay the condition.